These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24971999)

  • 1. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
    Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
    PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
    Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
    J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
    Tabara H; Naito Y; Ito A; Katsuma A; Sakurai MA; Ohno S; Shimizu H; Yabuta N; Nojima H
    PLoS One; 2011; 6(10):e26034. PubMed ID: 22022498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
    J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.
    Shoulars K; Rodriguez MA; Thompson T; Markaverich BM
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):41-50. PubMed ID: 19837161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
    J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
    Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
    Lou YF; Zou ZZ; Chen PJ; Huang GB; Li B; Zheng DQ; Yu XR; Luo XY
    PLoS One; 2014; 9(5):e97719. PubMed ID: 24874286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
    Zhou X; Zheng M; Chen F; Zhu Y; Yong W; Lin H; Sun Y; Han X
    Anat Rec (Hoboken); 2009 Aug; 292(8):1122-7. PubMed ID: 19645012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
    Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
    Neveu G; Ziv-Av A; Barouch-Bentov R; Berkerman E; Mulholland J; Einav S
    J Virol; 2015 Apr; 89(8):4387-404. PubMed ID: 25653444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.